{"title":"IL17/23抑制剂对银屑病患者亚临床动脉粥样硬化标志物的影响：一项观察性研究","authors":"Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos, Dimitrios Rigopoulos","doi":"10.1007/s13555-025-01549-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.</p><p><strong>Methods: </strong>This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).</p><p><strong>Results: </strong>In total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.</p><p><strong>Conclusions: </strong>Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.\",\"authors\":\"Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos, Dimitrios Rigopoulos\",\"doi\":\"10.1007/s13555-025-01549-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>To date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.</p><p><strong>Methods: </strong>This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).</p><p><strong>Results: </strong>In total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.</p><p><strong>Conclusions: </strong>Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.</p>\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01549-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01549-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.
Introduction: To date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.
Methods: This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).
Results: In total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.
Conclusions: Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
